Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma.

MLA

Jo, Jae-Cheol, et al. “Yttrium-90 Ibritumomab Tiuxetan plus Busulfan, Cyclophosphamide, and Etoposide (BuCyE) versus BuCyE Alone as a Conditioning Regimen for Non-Hodgkin Lymphoma.” The Korean Journal of Hematology, vol. 47, no. 2, June 2012, pp. 119–25. EBSCOhost, https://doi.org/10.5045/kjh.2012.47.2.119.

APA

Jo, J.-C., Yoon, D. H., Kim, S., Park, J. S., Park, C.-S., Huh, J., Lee, S.-W., Ryu, J.-S., & Suh, C. (2012). Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. The Korean Journal of Hematology, 47(2), 119–125. https://doi.org/10.5045/kjh.2012.47.2.119

Chicago

Jo, Jae-Cheol, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Chan-Sik Park, Jooryung Huh, Sang-Wook Lee, Jin-Sook Ryu, and Cheolwon Suh. 2012. “Yttrium-90 Ibritumomab Tiuxetan plus Busulfan, Cyclophosphamide, and Etoposide (BuCyE) versus BuCyE Alone as a Conditioning Regimen for Non-Hodgkin Lymphoma.” The Korean Journal of Hematology 47 (2): 119–25. doi:10.5045/kjh.2012.47.2.119.